NCT00923481 · OUTCOME

Number of Participants With Adverse Events

A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... · Source last updated 2015-09-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Participants
Interval / dispersion: Not reported
Time frame: 23 months

What was measured

Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.

Groups in this outcome

Multi-kinase Inhibitor Fosamatinib Disodium

200 mg BID was the administered dose for the initial part of the study and then a phase I dose escalation was added with 100 mg as the starting dose.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Multi-kinase Inhibitor Fosamatinib Disodium	37

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multi-kinase Inhibitor Fosamatinib Disodium	37	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
37

denoms

counts
group Id
OG000
value
37
units
Participants

description

Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.

groups

description
200 mg BID was the administered dose for the initial part of the study and then a phase I dose escalation was added with 100 mg as the starting dose.
id
OG000
title
Multi-kinase Inhibitor Fosamatinib Disodium

param Type

NUMBER

reporting Status

POSTED

time Frame

23 months

title

Number of Participants With Adverse Events

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice